Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Am J Obstet Gynecol. 2010 Dec 17;204(3):211.e1–211.e6. doi: 10.1016/j.ajog.2010.10.898

Table 4.

Frequency of initial treatment emergent events by randomized treatment group among those reporting at least one adverse event*

Event Metronidazole 500mg n(%) Tinidazole 1g n(%) Tinidazole 500mg n(%) p value
Yeast infection 32 (29.3) 27 (24.5) 33 (25.0) 0.67
Nausea/vomiting 22 (20.2) 34 (30.9) 26 (19.7) 0.08
Bad taste 12 (11.0) 46 (41.8) 20 (15.2) <0.001
Diarrhea 4 (3.7) 6 (5.5) 1 (0.8) 0.10
Anorexia 1 (0.8) 5 (4.5) 7 (5.3) 0.17
Headache 16 (14.7) 27 (24.5) 22 (16.7) 0.13
Total Number of Subjects with at Least 1 Adverse Event 109 110 132
*

Subjects can experience more than one adverse event; the percents reperesent the number of subjects with that incident event out of the total number of individuals in each treatment group who experienced at least one adverse event.